In acute leukemia models, however, Mertk-/- or pharmacologic MERTK inhibition had similar effects, providing strong evidence that MERTK inhibition is sufficient to elicit anti-tumor immunity [65,66,67]. The gene discussed is MERTK; the disease is neoplasm.